Shijiazhuang Yiling Pharmaceutical China
Shijiazhuang Yiling Pharmaceutical
The main business of Ling Pharmaceutical Industry is the R&D, production and sales of traditional Chinese medicine. In the field of diseases, the company ranks first in the field of medication for cardiovascular, cerebrovascular and respiratory diseases. Among its products, Lianhua Qingwen Capsules/Granules for treating colds and influenza entered the National Essential Medicines Catalogue (2018 edition), which is the basic medicine for treating colds.Yiling Pharmaceuticals provide jujube seed oil,you can know it.
On November 20, 2018, the General Office of the State Health Commission and the Office of the State Administration of Traditional Chinese Medicine jointly issued the Influenza Diagnosis and Treatment Program (Revised Version 2018). Lianhua Qingwen Capsule/Granule was once again listed as recommended medication. At the same time, Jinhua Qinggan Granule, Qingkailing Granule (Capsule, Soft Capsule, Tablet), Shufeng Jiedu Capsule, Yinqiao Jiedu Capsule, Sangju were also recommended.
All along, cold is a common and multiple disease, and cold medicine is almost a household drug. Because of its high incidence and wide susceptibility, the market demand for cold medicine has been rising. According to Zhongkang CMH data, cold medicine is the largest category in the retail market.
According to incomplete statistics, 75% of the people in China suffer from a cold at least once a year, that is to say, nearly 1 billion people need to use cold medicine at least once a year. Data show that the average cost of cold medication is 25 yuan per time.
The compound growth rate of cold medicines is 15% between 2012 and 2016, and the market scale will reach 95 billion yuan by 2022.
The market of Zhongcheng cold medicine has been fiercely competitive. According to the data of MineNet, the sales revenue of Chinese patent medicines for cold medicines in TOP10 in 2017 was 6.54%, 6.24%, 4.74%, 4.21% and 3.75% of the market share of Shufeng Jiedu Capsule, Lianhua Qingwen Granule, Zukamu Granule, Lianhua Qingwen Capsule and Shuanghuanglian Granule of Harbin Children's Pharmaceutical in Anhui Jiren Pharmaceutical Industry.
According to the data of Zhongkang Information, in the TOP10 of OTC terminal cold medicines in 2018, the top five were Huarun 399 (000999.SZ) Ganmaoling granules, Pudilan Xiaoyan oral liquid of Jichuan Pharmaceutical Industry (600566.SH), Huoxiang Zhengqi oral liquid of Taiji Group (600129.SH), Huarun 399 Compound Ganmaoling granules and Lianhuaqing of Yiling Pharmaceutical Industry. Pestilence Capsules, Andrographolide Dropping Pills of Tianshili (600535. SH) and Pudilan Anti-inflammatory Tablets of Yunnan Baiyao (000538. SZ) also ranked in the top 10.
Shijiazhuang Yiling Pharmaceutical
was awarded the “Most Cooperative Industrial Brand Enterprise of Chinese Chain Drugstores”
On July 15th, 2018 China's top 100 pharmaceutical industry list was held in Jinan. As the highlight of the 2019 National Pharmacy Week, “2019 China Chain Drugstore's Most Cooperative Industrial Brand Enterprise” was unveiled in Jinan Shandong Building! Yiling Pharmaceuticals praised “2019 China Chain Pharmacy Most Cooperative Industrial Brand Enterprise”.
This is the second industry honor that Lingling Pharmaceuticals has won after the “Top 100 Chinese Pharmaceutical Industry” in the 2019 pharmacy week.
The 2019 National Pharmacy Week and China Pharmaceutical Innovation and Development Summit, the theme of “Reconstruction of Value – Searching for Growth, Expanding Boundaries, and Exploring the Future”, under the current situation of rapid changes in policy and market environment and accelerated restructuring of the pharmaceutical retail industry, Look for new growth points in the hot policy of the pharmaceutical industry, develop and break through the development boundary in the new competitive environment, and seize the commanding heights of the future.
In the past 27 years, Yiling Pharmaceutical has always adhered to the market leading and technology-driven innovation development strategy, and created a unique operation mode of “theory-clinical-scientific research-industry-teaching”.
He has undertaken and completed more than 30 national-level major projects such as the national “Eleventh Five-Year” support, the national “Twelfth Five-Year Plan” major new drug creation, the national key research and development plan, and more than 10 patent new drugs. More than 350 patents and 5 national science and technology awards have made Yiling Pharmaceuticals the leader in China's pharmaceutical industry.